# Selinexor, Daratumumab, and Dexamethasone (XDd) for Light-Chain Cardiac Amyloidosis

> **NCT07743957** · PHASE2 · NOT_YET_RECRUITING · sponsor: **Beijing Anzhen Hospital** · enrollment: 63 (estimated)

## Conditions studied

- Light-chain Cardiac Amyloidosis

## Interventions

- **DRUG:** XDd

## Key facts

- **NCT ID:** NCT07743957
- **Lead sponsor:** Beijing Anzhen Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-07-13
- **Primary completion:** 2028-02-01
- **Final completion:** 2028-06-01
- **Target enrollment:** 63 (ESTIMATED)
- **Last updated:** 2026-08-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07743957

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07743957, "Selinexor, Daratumumab, and Dexamethasone (XDd) for Light-Chain Cardiac Amyloidosis". Retrieved via MORVS 2026-10-20 from https://api.morvs.ai/clinical/NCT07743957. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*